Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
05/2003
05/01/2003WO2003034996A2 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
05/01/2003WO2003034987A2 Androgen receptor modulators and methods of use thereof
05/01/2003WO2003034903A2 Psma antibodies and protein multimers
05/01/2003WO2003034825A1 Anthelmintic composition
05/01/2003WO2003018018A3 Vinorelbine compositions and methods of use
05/01/2003WO2003013656A3 Non-peptide ccr1 receptor antagonists for the treatment of progressive renal fibrosis
05/01/2003WO2003007955A3 Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
05/01/2003WO2003003981A3 Compositions for improving mental performance
05/01/2003WO2003002109A8 Use of tyrosine kinase inhibitors for treating autoimmune diseases
05/01/2003WO2002102297A3 Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders
05/01/2003WO2002100351A3 A method for treating inflammatory diseases by administering a ppar-delta agonist
05/01/2003WO2002100336A3 Tissue-specific endothelial membrane proteins
05/01/2003WO2002099055A3 Cips as modifiers of the p53 pathway and method of use
05/01/2003WO2002099046A3 Spo11 as modifier of the p53 pathway and methods of use
05/01/2003WO2002098444A3 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
05/01/2003WO2002098347A3 Methods and compositions that affect melanogenesis (pfi-016cip/pct)
05/01/2003WO2002096435A3 Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
05/01/2003WO2002083712A3 Transporters and ion channels
05/01/2003WO2002076391A3 Microbial feeds for aquaculture and agriculture
05/01/2003WO2002074292A3 Hormone replacement therapy
05/01/2003WO2002074287A3 Antibacterial compositions containing of oxapenem-3-carboxylic acids and antibiotics
05/01/2003WO2002059356A3 Method for screening compounds for activity in treating an osteoclast related bone disease
05/01/2003WO2002058685A3 Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
05/01/2003WO2002049627A3 Antifungal compositions containing an antibiotic and one or more amidoamines
05/01/2003WO2002048165A3 Antiviral agents for treatment of flaviviridae infections
05/01/2003WO2002045704A3 Prevention and treatment of tachyphylactic response
05/01/2003WO2002045525A3 Aged companion pet diet
05/01/2003WO2002044113A9 Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
05/01/2003WO2002039995A3 Combination therapy for estrogen-dependent disorders
05/01/2003WO2002005834A3 Novel uses for thyroid hormones or thyroid hormone-like agonist compounds for treating dermis conditions
05/01/2003WO2002000244A3 Protein mixtures for wound healing
05/01/2003WO2001098478A3 Clk-2, cex-7 and coq-4 genes, and uses thereof
05/01/2003WO2001079291A3 Secreted proteins
05/01/2003US20030083739 For treating vascular in-stent restenosis; drug delivery
05/01/2003US20030083642 Devices and methods for the restoration of a spinal disc
05/01/2003US20030083466 cDNA clone MY1 that encodes a novel human 7-transmembrane receptor
05/01/2003US20030083465 Protein for use in treatment and prevention of angiogenesis
05/01/2003US20030083382 Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
05/01/2003US20030083380 Comprises 2-ketoethanoic acid for cosmetic conditions and dermatologic disorders
05/01/2003US20030083379 Rapidly absorbed liquid compositions
05/01/2003US20030083377 Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor
05/01/2003US20030083343 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
05/01/2003US20030083342 Combination of organic compounds
05/01/2003US20030083339 Using antagonists of the Angiotensin II type 2 receptor (AT2 receptor) for example candesartan cilexetil; combination treatment with an ACE inhibitor (angiotensin converting enzyme=ACE); drug screening assays
05/01/2003US20030083337 Optically active 3-[(2-piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists
05/01/2003US20030083322 For androgenic alopecia or hirsutism; physiologically tolerated film-forming agent and solvent, a plasticizer and compound such as 4-(5-methyl-2,4-dioxo-5-trifluoromethyl)-oxazolidin-3-yl)-2 -(trifluoromethyl)-benzonitrile
05/01/2003US20030083318 Therapy for neurodegenerative diseases
05/01/2003US20030083316 Dioxolane nucleosides and nucleoside analogues such as troxacitabine together with chemotherapeutic agents other than doxorubicin such as cytarabine, gemcitabine and idarubicin; synergistic mixture; treating leukemia, cancer
05/01/2003US20030083313 Means of tumor therapy
05/01/2003US20030083308 Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes and DNA viruses
05/01/2003US20030083298 Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis or growth of DMS
05/01/2003US20030083294 Enhancing or inhibiting the biological activity of nucleic acid ligands by administrating a modulator, to change the binding of the nucleic acid ligand for its target or degrading or cleaving
05/01/2003US20030083258 Modulation of leukocyte-endothelial interactions following ischemia
05/01/2003US20030083256 Compositions and methods for enhancing drug delivery across and into epithelial tissues
05/01/2003US20030083254 Heparanase-like proteins and nucleotides that encode them
05/01/2003US20030083246 Methods for treating rheumatic diseases using a soluble CTLA4 molecule
05/01/2003US20030083242 Methods and compositions for treating or preventing peripheral neuropathies
05/01/2003US20030083235 Such as alpha-O-linked glycopeptides with clustered glycodomains which are useful as anticancer agents
05/01/2003US20030083233 Aqueous mixtures of oxygen-carrying and non-oxygen carrying plasma expanders; oxygen-carrying component consists of hemoglobin-based oxygen carrier, non-oxygen carrying plasma expander consists of diluent; blood substitutes
05/01/2003US20030083228 Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction
05/01/2003US20030083226 Composition having reverse transcriptase inhibitor activity
05/01/2003US20030082769 Human papillomavirus E2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor binding pocket
05/01/2003US20030082743 Polypeptide sequences of human EDG-1c
05/01/2003US20030082725 DNA encoding a novel human inhibitor-of-apoptosis protein
05/01/2003US20030082685 Chemotherapeutic induction of egr-1 promoter activity
05/01/2003US20030082674 Genetically engineered receptor protein for use in the treatment of respiratory system disorders
05/01/2003US20030082672 Dna encoding galanin galr2 receptors and uses thereof
05/01/2003US20030082620 Novel human genes and gene expression products: II
05/01/2003US20030082612 Detection of mutant leptin receptor; obtain cells, extract nucleotide sequences, incubate with an oligonucleotide probe, detect hybridization, presence of hybridization, indicates defective receptor
05/01/2003US20030082513 Detecting cell to cell activity in sample; obtain cells, polarize, incubate with fluorescent dye, determine membrane potential of cells, monitor adjustment in membrane potenial between cells
05/01/2003US20030082286 Low calorie; sugar replacement
05/01/2003US20030082245 Anti-inflammatory agent and foods and drinks containing the same
05/01/2003US20030082226 Non-steroidal antiinflammatory drug formulations for topical application to the skin
05/01/2003US20030082224 Antitumor, anticancer agents
05/01/2003US20030082214 Oil in water emulsion containing antidepressant, anesthetics
05/01/2003US20030082184 Uses of mammalian cytokine; related reagents
05/01/2003US20030082180 Combination of compounds that inhibit the biological effects of tnf-alpha and cd95l in a medicament
05/01/2003US20030082176 Therapy for metabolism disorders
05/01/2003US20030082172 Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
05/01/2003US20030082169 System and method for the pretreatment of the endplates of an intervertebral disc
05/01/2003US20030082155 Antidiabetic agents; cell differentiation of stem cells
05/01/2003US20030082148 Methods and device compositions for the recruitment of cells to blood contacting surfaces in vivo
05/01/2003US20030082140 Increasing the amount of the cell differentiation associated protein, MDA-7 and decreasing RAS gene activity by administering a viral vector comprising an MDA-7 gene and an antisense ras oligonucleotide; treating pancreatic cancer
05/01/2003US20030082135 Pathway of RANTES-mediated chemokine synthesis in astrocytes and methods of use therefor
05/01/2003US20030082116 Adhesive compositions containing dual function stabilizers and active agents
05/01/2003US20030082108 Inhibitors of enzymes that metabolize arachidonic acid; peroxisome proliferator-activated receptors (ppar)
05/01/2003CA2465261A1 Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis
05/01/2003CA2464700A1 Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
05/01/2003CA2464695A1 Il-13 mutein proteins, antibodies, compositions, methods and uses
05/01/2003CA2464561A1 Methods of treatment using a gastric retained losartan dosage
05/01/2003CA2464403A1 Anthelmintic composition
05/01/2003CA2464344A1 Ee3-protein family and corresponding dna sequences
05/01/2003CA2464277A1 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
05/01/2003CA2464261A1 Apomorphine-containing dosage form for ameliorating male erectile dysfunction
05/01/2003CA2464239A1 Psma antibodies and protein multimers
05/01/2003CA2463975A1 Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
05/01/2003CA2463758A1 Salts formed of an at1-receptor antagonist and a cardiovascular agent
05/01/2003CA2463311A1 Androgen receptor modulators and methods of use thereof
05/01/2003CA2462163A1 Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
05/01/2003CA2461661A1 Use of histamine to treat liver disease
1 ... 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 ... 1151